Home > Treatment Options > Tumor Suppressors > Clinical Trials >

Lapatinib (Tykerb™)

Last Updated: 02/16/18

Status: Currently a NF2 Clinical Trial

Chemical Structure, Lapatinib

Trade Name Tykerb™
Synonyms: Tykerb, Lapatinib Ditosylate, GW572016, 231277-92-2,
GW 572016, Tycerb, 1xkk, Lapatinib (INN), Lapatinib [INN]
Pharmaceutical Company: GlaxoSmithKline
Legal Status: ℞ - Prescription Only
Administered By: Pill - Oral
Tumor Target: Vestibular Schwannoma
NF2 Trials:
Protein Target: TKI and EGFR Inhibitors
Formula C29H26ClFN4O4S
IUPAC N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-
ChemSpider 181006
PubChem CID 208908


Take Lapatinib at night instead of the morning to prevent fatigue.

Other Known Uses

Breast cancer and others.

Side Effects

Minimal Side Effects

Major side effects are uncommon. Since people with NF2 are taking these medications at a low dose, only minimal side effects are common. However, long term use is primarily where these major side effects take place. Monthly Blood and Urine Tests can usually point to an issue before it's a real problem. Talk to your doctor.

  • Memory Loss
  • Acne
  • Nail Infections
  • Vision - Light Sensitivity

Additional Side Effects to Watch for:

  • Liver Damage
  • Anemia
  • Low White Cell Count
  • Low Platlet Count
  • Risk of Infection
  • Nausea
  • Vomiting
  • Diarrhea
  • Belly Pain
  • Skin Irritation
  • Rash
  • Mouth Irritation
  • Numbness / Tingling of Hands and Feet
  • Fatigue
  • Irregular Menstrual Cycle

4. Warning:

Liver Damage: Look for dark urine, feeling tired, not hungry, nausea, vomiting or yellowing of skin and/or eyes.

What is NF2? | About Us | Treatment Options | Sitemap

Disclaimer: Neurofibromatosis Type 2 - Information and Services, www.nf2is.org, is not run by medical experts, affiliated with any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here, the accuracy of other sites to which this site links, or of sites that link to this site. - Read More

Copyright © 2008 - 2019